Accessibility StatementSkip Navigation FAIRBANKS, Alaska, Sept. 26, 2025 /PRNewswire/ - Contango ORE, Inc. ("Contango" or the "Company") (NYSE American: CTGO), is pleased to announce that it has closed its underwritten public offering (the "Offering") of common shares (the "Shares") of the Company consisting of 1,975,000 shares of its common stock at a public offering price of $20.00 per share to two institutional investors. In the Offering, Contango also offered a pre-funded warrant to purchase 525,000 sha ...

STEINHAUSEN, Switzerland, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) (“Transocean”) announced today the pricing of an underwritten public offering of 125,000,000 Transocean shares, par value $0.10, at a public offering price of $3.05 per share. The offering reflects an increase from the 100,000,000 Transocean shares originally proposed to be sold. The gross proceeds to Transocean from the offering, before deducting underwriting discounts and commissions and offering expenses, are expecte ...

CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the pricing of its upsized public offering of 11,108,055 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to MBX Biosciences from the offering, before deducting underwriting discounts and co ...

STEINHAUSEN, Switzerland, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Transocean Ltd. RIG ("Transocean") announced today that it intends to offer and sell 100,000,000 Transocean shares, par value $0.10, in an underwritten public offering. All of the shares subject to the offering are being offered by Transocean. In addition, Transocean expects to grant the underwriters a 30-day option to purchase up to an additional 15,000,000 shares in the offering at the public offering price, less underwriting discounts and commi ...

GOLETA, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ: ALMU) (“Aeluma” or “the Company”), a transformative semiconductor company specializing in high performance and scalable technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, Aeluma also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. ...

LIMASSOL, Cyprus, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Robin Energy Ltd. (NASDAQ:RBNE) ("Robin Energy" or the "Company"), an international ship-owning company providing energy transportation services globally, today announced the closing of its previously announced underwritten public offering of 5,769,230 shares of its common stock at a public offering price of $1.30 per share (the “Offering”). In connection with the Offering, the underwriter partially exercised its overallotment option and purchased an addi ...

公司融资活动 - 公司完成承销公开发行定价 发行5,769,230股普通股 每股定价1.30美元[1] - 本次发行预计总收益约750万美元 扣除承销折扣和费用前[1] - 承销商获得45天期权 可额外购买865,385股普通股[1] - 发行预计于2025年9月12日左右完成 需满足常规交割条件[1] - Maxim Group LLC担任本次发行独家簿记管理人[2] - 发行净收益将用于营运资金和一般公司用途[2] 法律与监管文件 - 发行依据Form F-3架式注册声明进行 文件号333-286726[3] - 注册声明于2025年4月24日提交SEC 同年4月28日宣布生效[3] - 最终招股说明书补充文件将提交SEC 可通过Maxim Group获取副本[3] 公司业务概况 - 公司为国际船舶所有企业 提供全球能源运输服务[5] - 目前拥有1艘Handysize型油轮和1艘LPG运输船[5] - 船舶主要运输石化气体和精炼石油产品全球范围[5] 联系方式 - 投资者关系可通过ir@robinenergy.com邮箱联系[8]

公司融资活动 - Robin Energy Ltd 宣布开始公开发行普通股股票或预融资认股权证 所有股份均由公司出售 [1] - 本次发行由Maxim Group LLC担任唯一账簿管理人 [2] - 发行所得净收益计划用于营运资金和一般公司用途 [2] 发行法律依据 - 发行依据Form F-3有效货架注册声明进行 注册号333-286726 于2025年4月24日提交SEC并于4月28日宣布生效 [3] - 初步招股说明书补充文件及相关 prospectus 将提交SEC并在其网站公布 [3] 公司业务概况 - Robin Energy为国际船东公司 提供全球能源运输服务 [5] - 公司拥有1艘Handysize型油轮和1艘LPG运输船 专门运输石化气体和精炼石油产品 [5]

公司融资活动 - 公司宣布拟进行普通股承销公开发行[1] - 发行净收益计划用于营运资金及一般公司用途包括债务偿还和偿债[1] - 发行计划仍需取决于市场及其他条件[1]

融资方案核心条款 - 公司进行承销公开发行 普通股74,811,404股 每股发行价0.52美元 同时向特定投资者发行预融资权证 可购买21,342,442股普通股 每份权证价格0.5199美元 [1] - 预融资权证定价相当于普通股发行价减去每股0.0001美元行权价 [1] - 总融资规模预计约5000万美元 需扣除承销折扣及发行费用 [1] - 承销商获30天期权 可额外购买14,423,076股普通股 [1] - 预计交易完成时间为2025年8月22日 [1] 承销安排与法律依据 - Cantor担任本次发行唯一账簿管理人 [2] - 发行依据S-3架式注册声明（文件号333-267643） 于2022年9月28日提交 10月5日获SEC批准生效 [4] - 发行文件包括招股说明书补充文件及配套招股书 初步文件已于2025年8月20日提交SEC [5] 资金用途规划 - 净收益将结合现有现金及等价物 用于VYD2311临床项目的试验方案开发与推进 [3] - 资金将投入呼吸道合胞病毒（RSV）和麻疹等管线项目的研发 [3] - 支持SPEAR研究组评估单抗疗法对长期新冠及疫苗接种后综合征的作用 [3] - 部分资金用于营运资本及其他一般公司用途 [3] 公司背景信息 - 公司为生物制药企业 专注于预防严重病毒传染病 首要目标为SARS-CoV-2 [7] - 拥有行业独特集成技术平台 用于评估、监测和开发抗体 [7] - 2024年3月获美国FDA授予单克隆抗体候选药物紧急使用授权（EUA） [7]